The Lancet: The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial

The Lancet: The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial

Co Authored by Cyril P Clarke, Vice President Translational Medicine and Jonathan H Goldman, Executive Vice President Strategic Programs and Alliance Management

Click Here to view on The Lancet.com